Año 2021 / Volumen 113 / Número 6
Revisión
Risk factors and management strategies associated with non-response to aminosalicylates as a maintenance treatment in ulcerative colitis

447-453

DOI: 10.17235/reed.2021.7797/2021

David Martí-Aguado, María Pilar Ballester, Miguel Mínguez,

Resumen
Aminosalicylates (5-ASA) are used as the first-line maintenance treatment in patients with mild-moderate ulcerative colitis (UC). Early identification of patients at high risk for 5-ASA non-response and appropriate therapeutic escalation are essential to avoid disease progression. However, the absence of a standardized definition for treatment success makes this a challenging task. The focus of the current review was to describe the risk factors and management strategies associated with 5-ASA non-response. Rates of 5-ASA failure can vary from 17 % to 75 % according to different success definitions, of which clinical relapse is the most prevalent and studied condition. Younger age and endoscopic activity at diagnosis, extensive colitis, early need for corticosteroids, elevated inflammatory markers and non-adherence are consistent risk factors of 5-ASA failure. Given the effectiveness, safety profile and tolerability of this medication, therapy optimization is critical before treatment escalation. Combined use of systemic and topical therapy at an appropriate dose in a once-daily administration and control of adherence could improve success rates.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Fumery M, Singh S, Dulai PS, et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16(3): 343-356.e3.
2. Marti-Aguado D, Ballester MP, Tosca J, et al. Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study. United European Gastroenterol J. 2019 Oct;7(8):1042-1050.
3. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus. Gastroenterology. 2015; 148(5): 1035-1058.e3.
4. Schoepfer AM, Vavricka S, Zahnd-Straumann N, et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis. 2012; 6(4): 412-418.
5. Fukuda T, Naganuma M, Takabayashi K, et al. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine. J Gastroenterol Hepatol. Epub ahead of print 2020 Apr 6. DOI:10.1111/jgh.15059.
6. Ballester MP, Marti-Aguado D, Fullana M, et al. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. Int J Colorectal Dis. 2019; 34(6): 1053-1059.
7. Fukuda T, Naganuma M, Sugimoto S, et al. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry. PLoS ONE. 2017; 12(11): e0187737.
8. Nagahori, M., Kochi, S., Hanai, H. et al. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterol. 2017; 17: 47.
9. Garcia-Planella E, Mañosa M, Chaparro M, et al. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. Scand J Gastroenterol. 2018; 53(2): 152-157.
10. Prosberg MV, Vester-Andersen MK, Andersson M, et al. Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study. Inflamm Bowel Dis. 2016; 22(4): 925-932.
11. Richter JM, Arshi NK, Oster G. Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. Can J Gastroenterol Hepatol. 2016; 2016: 6928710.
12. Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther. 2015; 42: 549–558.
13. Yokoyama K, Kobayashi K, Mukae M, et al. Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis. Gastroenterol Res Prac. 2013; 2013: 192794.
14. Lee HJ, Jung ES, Lee JH, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Hepatogastroenterology. 2012; 59: 1415–1420.
15. Garcia-Planella E, Mañosa M, Van Domselaar M, et al. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis. 2012; 44: 206–210.
16. Bello C, Belaiche J, Louis E, et al. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011; 5: 196–202.
17. Höie O, Wolters F, Riis L, et al. Ulcerative colitis: Patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007; 102: 1692–1701.
18. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001; 120: 13–20.
19. Navarro F, Hanauer SB. Treatment of Inflammatory Bowel Disease: Safety and Tolerability Issues. Am J Gastroenterol. 2003; 98:S18–S23.
20. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2005; 100:1345–1353
21. Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: Results from a randomized controlled study. Inflamm Bowel Dis. 2007;13:1115–1120.
22. Pica R, Cassieri C, Cocco A, et al. A randomized trial comparing 4.8 vs. 2.4g/day of oral mesalazine for maintenance of remission in ulcerative colitis. Digest Liver Dis. 2015; 47:933–937.
23. Suzuki Y, Iida M, Ito H, et al. 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial. Inflamm Bowel Dis. 2017; 23:822–832.
24. Kane SV, Robinson A. Review article: understanding adherence to medication in ulcerative colitis –innovative thinking and evolving concepts. Aliment Pharmacol Ther. 2010; 32(9):1051–1058.
25. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011; 5:477–483.
Artículos relacionados

Carta

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Carta

Colitis linfocítica con hallazgos macroscópicos

DOI: 10.17235/reed.2023.9497/2023

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Carta

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Imagen en Patología Digestiva

Esófago negro

DOI: 10.17235/reed.2022.9217/2022

Carta

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Carta

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Carta

Upadacitinib en colitis ulcerosa refractaria

DOI: 10.17235/reed.2022.8870/2022

Carta

Afectación intestinal secundaria a tocilizumab

DOI: 10.17235/reed.2022.8818/2022

Carta

Colitis isquémica inducida por AINE

DOI: 10.17235/reed.2022.8605/2022

Carta

Neumonitis intersticial por mesalazina en la era COVID

DOI: 10.17235/reed.2022.8635/2021

Imagen en Patología Digestiva

Neumatosis portal en paciente con colitis por Salmonella severa

DOI: 10.17235/reed.2021.8090/2021

Imagen en Patología Digestiva

Phlebosclerotic colitis: an unusual cause of abdominal pain and hematochezia

DOI: 10.17235/reed.2020.7358/2020

Carta

Efecto del Adacolumn® en colitis ulcerosa con COVID-19

DOI: 10.17235/reed.2020.7156/2020

Revisiones Rápidas

COVID-19, coronavirus, SARS-CoV-2 and the small bowel

DOI: 10.17235/reed.2020.7137/2020

Carta

Síndrome de Sweet en el brote grave de colitis ulcerosa

DOI: 10.17235/reed.2020.6995/2020

Editorial

Trasplante de pulmón y disfunción esofágica

DOI: 10.17235/reed.2018.5693/2018

Imagen en Patología Digestiva

Immune mediated colitis caused by lung cancer treatment with atezolizumab

DOI: 10.17235/reed.2017.5060/2017

Original

Colonic diverticulosis and the metabolic syndrome: an association?

DOI: 10.17235/reed.2017.5009/2017

Carta al Editor

Colitis ulcerosa con afectación gástrica y duodenal

DOI: 10.17235/reed.2017.4685/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Carta al Editor

Colitis isquémica en una deportista: “correr no siempre es saludable”

DOI: 10.17235/reed.2016.4184/2015

Caso Clínico

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Imagen en Patología Digestiva

Ileocolitis fatal por Camplobacter jejuni

Caso Clínico

Severe ischemic colitis following olanzapine use - A case report

DOI: 10.17235/reed.2016.3944/2015

Imagen en Patología Digestiva

Colitis infecciosa nodular: un hallazgo inusual

Caso Clínico

Colitis isquémica inducida por olanzapina

DOI: 10.17235/reed.2015.3856/2015

Instrucciones para citar
Martí-Aguado D, Ballester M, Mínguez M. Risk factors and management strategies associated with non-response to aminosalicylates as a maintenance treatment in ulcerative colitis. 7797/2021


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1187 veces.
Este artículo ha sido descargado 256 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 15/01/2021

Aceptado: 21/01/2021

Prepublicado: 11/02/2021

Publicado: 04/06/2021

Tiempo de revisión del artículo: 2 días

Tiempo de prepublicación: 27 días

Tiempo de edición del artículo: 140 días


Compartir
Este artículo ha sido valorado por 2 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas